Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy.Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free.
Exciting stuff and this is from 2 years ago. Bring on them human trials!